Qin Yu

Qin Yu has a diverse and extensive work experience in the biotechnology and pharmaceutical industry. Qin currently holds the position of VP of Research at Vesigen Therapeutics, Inc., where they started in June 2023. Prior to this, Qin Yu served as the VP of Discovery at Carmine Therapeutics from November 2021 to April 2023. Qin also worked as a Senior Director at Ascidian Therapeutics from January 2020 to November 2021.

Qin Yu has a strong background in platform technology and scientific research. Qin held the position of Director, Platform Technology at Rubius Therapeutics from February 2018 to January 2020, and they previously served as a Principal Scientist at the same company from September 2015 to February 2018. Before joining Rubius Therapeutics, Qin Yu worked as a Principal Scientist at AstraZeneca R&D from May 2011 to August 2015.

Qin'searlier experiences include the role of Investigator II at Novartis from June 2009 to May 2011, and they worked as a Scientist at Phenomix Corporation from September 2006 to February 2009. Qin Yu also held research positions at the Salk Institute for Biological Studies from 2002 to 2006, where they started as a Postdoctoral fellow and later became a Staff scientist. Qin began their research career as a Postdoctoral fellow at the University of Alabama at Birmingham from 2001 to 2002.

Overall, Qin Yu's work experience demonstrates their expertise in research, development, and management roles within the biotechnology and pharmaceutical industry.

Qin Yu has a Ph.D. in Virology from the University of Alabama at Birmingham. Prior to that, they obtained an M.S./B.S. degree in Cell Biology from Peking University.